Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Stock analysts at Zacks Research increased their FY2024 earnings estimates for shares of Immunovant in a research note issued on Thursday, April 25th. Zacks Research analyst E. Bagri now expects that the company will post earnings of ($1.72) per share for the year, up from their prior forecast […]
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Julia G. Butchko sold 10,115 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $29.06, for a total value of $293,941.90. Following the completion of the transaction, the insider now directly owns 451,627 shares in […]
Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Stock analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Immunovant in a research note issued on Monday, April 8th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of ($0.49) for the quarter, down from their […]
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 9,350,000 shares, an increase of 7.7% from the February 29th total of 8,680,000 shares. Based on an average daily volume of 1,320,000 shares, the […]
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Truist Financial in a report issued on Monday, Benzinga reports. They presently have a $48.00 price target on the stock. Truist Financial’s price target indicates a potential upside of 47.28% from the stock’s previous close. A number of […]